| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
TPAP does not have a defined pharmacological target. It is an oxidizing agent used in organic synthesis. Its mechanism of action is chemical: the ruthenium(VII) center in the perruthenate ion acts as a mild, selective oxidant, converting primary alcohols to aldehydes and secondary alcohols to ketones under mild conditions.
|
|---|---|
| ln Vitro |
Tetrapropylammonium perruthenate is a biochemical reagent that can be utilized in research pertaining to life sciences as an organic substance or biological material.
In vitro, TPAP is used as a mild and selective oxidizing agent for the oxidation of alcohols to carbonyl compounds. It is often used in combination with N-methylmorpholine N-oxide (NMO) as a co-oxidant in catalytic amounts. The compound is a valuable reagent in organic synthesis for the preparation of aldehydes and ketones. |
| ln Vivo |
In vivo activity data for TPAP are not available, as the compound is an oxidizing agent used for in vitro synthesis. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile.
|
| Enzyme Assay |
For in vitro chemical synthesis, TPAP is used as an oxidizing agent. Standard protocols involve adding a catalytic amount of TPAP (typically 1-5 mol%) to a solution of the alcohol in an appropriate solvent (e.g., dichloromethane) along with a co-oxidant such as NMO. The reaction is stirred at room temperature until complete, and the product (aldehyde or ketone) is isolated by standard workup procedures.
|
| Cell Assay |
For in vitro cell-based experiments, TPAP is not typically used directly in cell culture. It is a chemical reagent used for organic synthesis. The compound may be used in the synthesis of compounds that are subsequently tested in cell-based assays.
|
| Animal Protocol |
In vivo animal studies for TPAP are not applicable, as the compound is an oxidizing agent used for synthesis. No animal studies have been conducted for this compound as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for TPAP are not available, as the compound is not a drug and is not administered to living organisms. The compound is a solid and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
TPAP is a research chemical and should be handled with appropriate laboratory safety precautions. As a ruthenium-containing compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
Tetrapropylammonium perruthenate (TPAP) (CAS 114615-82-6) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary application is as a mild and selective oxidizing agent for the oxidation of alcohols to aldehydes and ketones in organic synthesis.
|
| Molecular Formula |
C12H28NO4RU
|
|---|---|
| Molecular Weight |
351.43
|
| Exact Mass |
352.106
|
| CAS # |
114615-82-6
|
| PubChem CID |
127020979
|
| Appearance |
Brown to black solid powder
|
| Melting Point |
160ºC
|
| LogP |
2.968
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
18
|
| Complexity |
80.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Ru].O([H])[H].O([H])[H].O([H])[H].[O-][H].[N+](C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
HUCLFLGLPCVDMZ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C12H28N.4H2O.Ru/c1-5-9-13(10-6-2,11-7-3)12-8-4;;;;;/h5-12H2,1-4H3;4*1H2;/q+1;;;;;/p-1
|
| Chemical Name |
ruthenium;tetrapropylazanium;hydroxide;trihydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (142.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8455 mL | 14.2276 mL | 28.4552 mL | |
| 5 mM | 0.5691 mL | 2.8455 mL | 5.6910 mL | |
| 10 mM | 0.2846 mL | 1.4228 mL | 2.8455 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
